Xtandi

Pharma

FDA approves use of Bayer's Nubeqa in all patients with mCSPC

Bayer has scored an important FDA label expansion for Nubeqa, which now can be used by all patients with metastatic castration-sensitive prostate cancer.

Kevin Dunleavy Jun 4, 2025 11:38am

FDA advisors unanimously reject Pfizer's Talzenna expansion bid

May 22, 2025 10:20am

Pfizer details survival win in bid for broad prostate cancer nod

Feb 13, 2025 10:00am

Pfizer targets broad Talzenna label in prostate cancer

Oct 10, 2024 10:18am

J&J's Erleada shows survival edge over Xtandi in real-world study

Oct 2, 2024 2:42pm

Pfizer sees 8 blockbuster cancer drugs from each focus area

Jun 13, 2024 12:45pm